| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
It is anticipated that sodium NAAD will only be generated in peripheral blood mononuclear cells (PBMC) during the production of NAD+ from tryptophan and NA2, increasing from less than 20 nM to as high as 0.91 μM [1]. The amidation of nicotinic acid adenine dinucleotide (NAAD) to produce the enzyme cofactor nicotinamide adenine dinucleotide (NAD) is catalyzed by nicotinamide adenine dinucleotide synthase (NADS) [2].
|
|---|---|
| ln Vivo |
When mice were given niacin (NA) orally, their liver NA reached its peak in 15 minutes (340 pmol/mg). Hepatic NAD+ increases from a baseline of 990 to 2200 at two hours after gavage, after the appearance of hepatic NA, and the anticipated peak of 220 NAAD sodium arrives one hour later [1]. It has been observed that when mice are given intraperitoneally (IP) injections of 500 mg/kg radioactive nicotinamide (Nam), sodium NAAD accumulates in their livers. In contrast, NAAD sodium was found in the kidney, ovary, lung, heart, and brain of mice given an intraperitoneal injection of 500 mg/kg NA in addition to the liver [1]. NAAD sodium was not found in Nam.
|
| References |
| Molecular Formula |
C21H25N6NAO15P2
|
|---|---|
| Molecular Weight |
686.39
|
| Exact Mass |
686.075
|
| CAS # |
104809-30-5
|
| Related CAS # |
6450-77-7 (free);104809-30-5 (sodium);
|
| PubChem CID |
91872645
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
45
|
| Complexity |
1110
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)([O-])OP(=O)([O-])OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)O.[Na+]
|
| InChi Key |
LFHLUTZTSGEADU-RHANTIMGSA-M
|
| InChi Code |
InChI=1S/C21H26N6O15P2.Na/c22-17-12-18(24-7-23-17)27(8-25-12)20-16(31)14(29)11(41-20)6-39-44(36,37)42-43(34,35)38-5-10-13(28)15(30)19(40-10)26-3-1-2-9(4-26)21(32)33;/h1-4,7-8,10-11,13-16,19-20,28-31H,5-6H2,(H4-,22,23,24,32,33,34,35,36,37);/q;+1/p-1/t10-,11-,13-,14-,15-,16-,19-,20-;/m1./s1
|
| Chemical Name |
sodium;[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [(2R,3S,4R,5R)-5-(3-carboxypyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate
|
| Synonyms |
NAAD Na, NaAD; NAAD Na salt; NAAD sodium salt
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~145.69 mM)
DMSO : ~10 mg/mL (~14.57 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (1.46 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (1.46 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1 mg/mL (1.46 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4569 mL | 7.2845 mL | 14.5690 mL | |
| 5 mM | 0.2914 mL | 1.4569 mL | 2.9138 mL | |
| 10 mM | 0.1457 mL | 0.7284 mL | 1.4569 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
